One surprising feature is the appearance of paradoxical pro-inflammatory reactions in a subset of AD patients treated with the IL-4Rα blocker dupilumab12,13, which has not been observed in individuals with other type 2 diseases, such as allergic asthma14. This evidence concerns the gene IL4R and Alzheimer disease.